Skip to main content

Discovery of microRNA

The discovery of microRNA wins the 2024 Nobel Prize in physiology

These tiny bits of genetic material play a big role in making sure cells work as they should



Tiny bits of genetic material known as microRNAs help control how cells throughout the body produce proteins. And that may give these genetic bits an outsized role in health and disease. For the discovery of microRNAs, two scientists will take home this year’s Nobel Prize in physiology or medicine.

Their award was announced October 7 at the Karolinska Institute in Stockholm, Sweden.

Victor Ambros and Gary Ruvkun will split the prize of 11 million Swedish kroner (about $1 million). Ambros works at the University of Massachusetts Chan Medical School. It’s in Worcester. Ruvkun is based at Harvard Medical School in Cambridge, Mass.

When microRNA was discovered, it “introduced a new and unexpected [method] of gene regulation,” said Olle Kämpe. Vice Chair of the Nobel Committee that made this award, Kämpe spoke at the prize’s announcement.

The two new Nobel laureates “are both brilliant scientists and wonderful people,” says H. Robert Horvitz. He’s a biologist at MIT in Cambridge, Mass. He knows Ambros and Ruvkun. At one time, they worked in his lab.


Controlling protein production

Every cell in the body contains the same set of DNA. These molecules hold the instructions that every cell needs to make the proteins that do various jobs throughout the body. Those jobs include making muscles contract. Or helping the gut digest food. Or sending signals via nerves to the brain.

But if every cell has the same DNA, how do different types of cells know to make only the proteins needed for their particular jobs? A process called gene regulation does this. It helps each cell use only the right bits of DNA when it comes time to make proteins.

Here’s how microRNA helps regulate genes.

DNA holds the protein-making instructions in long-term storage. Cells don’t convert those DNA data directly into proteins. That genetic material is too valuable and much too big. Instead, cells copy data from DNA into molecules called messenger RNA, or mRNA. That copying process is known as transcription.

Mini machines in each cell read the mRNA instructions to build proteins. That process is called translation. (This is because the cell reads instructions in one chemical language, RNA, and then converts it to a different one, proteins.)

It’s the step between copying DNA and translating mRNA where microRNAs work.

These tiny, micro snippets of RNA latch onto much longer mRNAs. Any mRNA that has microRNAs clinging to it will break down. That prevents its instructions from being made into a protein. This process is important because cells need to make just the right proteins at the correct time. MicroRNAs help make sure the process goes smoothly.

MicroRNAs “are not on-off switches,” adds Tamas Dalmay. Instead, they work like a dimmer switch to dampen production of proteins. Dalmay is a molecular biologist at the University of East Anglia in Norwich, England.

MicroRNA’s humble origins

The discovery of microRNA goes back to a tiny worm that refused to grow up.

Ambros and Ruvkun were working in Horvitz’s lab on this see-through worm, called C. elegans. The pair worked to discover key steps in the worm’s development controlled by two bits of DNA, or genes. One gene was called lin-4. The other was lin-14.

Worms with a mutant form of lin-4 repeated certain steps in the larval stage of its growth. The result: Their bodies never made some adult parts.

Ambros narrowed the location of lin-4 in the worm’s DNA. But he found no protein-making gene there. Instead, he saw little bits of RNA showing up. At first, he brushed them off as some sort of grime. “It turned out that was the microRNA that we’re all talking about,” Ambros said at a news conference on October 7. Yet it was “so unexpected that we had kind of ignored it for a while as just, you know, schmutz.”

In 1993, Ambros discovered that lin-4 makes a microRNA. Ruvkun found that the lin-4 microRNA latches onto part of the lin-14 mRNA. That linkage turns down production of lin-14 protein. The lin-14 protein, in turn, regulates other genes needed for the worm to mature.

This way of controlling protein-making was unexpected and entirely new. “It wasn’t really taken super seriously because it was in this little worm,” recalls Luisa Cochella. “People thought this was something that these funny worms do.” Cochella is a molecular biologist at the Johns Hopkins School of Medicine. That’s in Baltimore, Md.

Seven years later, Ruvkun went on to find that many animals have a microRNA called let-7. That includes humans. “That’s when people noticed,” Cochella says. It “started a frenzy to find all the microRNAs that are present in animals.”


Uploading: 418767 of 418767 bytes uploaded.

A little worm’s big legacy

More than 1,000 microRNAs are now known to regulate genes in people. Other animals and plants also use them. Some microRNAs evolved a long time ago. Those old types tend to control basic life processes common to all plant and animal cells. Newer microRNAs tend to regulate processes found only in certain species.

When gene regulation errs, it can lead to disease. So microRNAs not only play an important role in the workings of healthy cells. For instance, malfunctioning microRNAs play key roles in cancer, pain, itchiness and eye diseases.

“The critical role that microRNAs play in health and disease has become more and more apparent,” said David Brown. He’s the president of the academic medical centers of Mass General Brigham in Boston. He spoke at a news conference honoring Ruvkun on October 7.

New disease treatments based on microRNAs are now being tested in people. These include treatments for heart disease and cancer.

The discovery of microRNA came “completely out of the blue! And it shows that curiosity research is very important,” Kämpe said. “They were looking at two worms that looked a bit funny and decided to understand why. Then, they discovered an entirely new mechanism for gene regulation. I think that’s beautiful.”

microRNA discovery, gene regulation, post-transcriptional regulation, cancer biology, disease biomarkers, cell differentiation, apoptosis, immune response, cardiovascular diseases, neurological disorders, miRNA dysregulation, personalized medicine, therapeutic targets, miRNA profiling, next-generation sequencing, gene expression, RNA interference, cancer therapeutics, small non-coding RNA, molecular diagnostics.

#microRNA #miRNAdiscovery #generegulation #cancerbiology #biomarkers #cellfunction #apoptosis #immuneresponse #cardiovasculardisease #neurologicaldisorders #dysregulation #personalizedmedicine #miRNAtargets #miRNAprofiling #nextgensequencing #RNAi #therapeutics #smallRNA #moleculardiagnostics #diseasebiomarkers

International Conference on Genetics and Genomics of Diseases 



 

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...